Skip to main content

Marizyme

  • About
      • Back
      • Overview
      • Executive Management
      • Board of Directors
      • Corporate Governance
  • Products
      • Back
      • Overview
      • DuraGraft®
      • Krillase®
      • MATLOC™ Platform
  • Clinical
      • Back
      • Publications
      • DuraGraft Publications
      • MATLOC Publications
  • Investors
  • Contact
      • Back
      • Contact Us
  • Sign Up
  • Language
      • Back
      • GER
adobe stock 229690447 preview

Products
MATLOCTM Platform

  • Overview
  • DuraGraft®
  • Krillase®
  • MATLOC™ Platform

Technology MATLOC™ Platform

group 3469

A proprietary point-of-care, lab-on-chip technology and patent pending for CKD assessment

 

MATLOC™

Chronic Kidney Disease (CKD):

 

common
Common
costly
Costly
harmful
Harmful

Kidney Failure Heart Disease Death
treatable 1
Treatable
37 million
HAVE CKD
American adults (roughly every 1 in 10) are estimated to have CKD. It is the 9th leading cause of death in the U.S.


80 million
AT RISK
Diabetes and high blood pressure accounts for roughly 70% of all CKD cases.


$120 billion

In Medicare costs, 2017, for all people with all stages of CKD.



90%
OF PEOPLE
who have CKD don’t know they have it.




Early diagnosis and treatment IS KEY

MATLOCTM Platform Pipeline

MATLOC has the potential to test for multiple biomarkers for effective disease screening and diagnosis at point-of-care.

 

group 2181
matloclogo1st Generation*
Screening Device
 
 
 
  • For care provider use in and outside the clinic
  • Easy use with lab-on-chip insert
  • Quantitatively measures urine ACR; Albumin-to-creatinine ratio (ACR)
  • Device will be handheld with Bluetooth capabilities
  • Quantitative results will transfer to smartphone cloud-based App

group 3470

group 2182
matloclogo2nd Generation*
Diagnostic Device
 
 
 
 
All the features of MATLOC 1, PLUS:
  • The ability to test for blood based eGFR
  • MATLOC 2 could revolutionize CKD care by providing accessible, inexpensive, quantitative and integrated CKD screening, diagnosis, and risk prediction analysis
  • There are currently no quantitative hand-held, point-of-care diagnostic devices available for the measurement of both ACR and eGFR.
imgfooter

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

 

Investors

  • Back
  • Stock Info
  • SEC Filings
  • Corporate Governance

Contact

  • Back
  • Contact Us
  • Sign Up
 

Get In Touch 

noun map 223137 555 Heritage Drive, Ste. 205,
Jupiter, FL 33458
noun phone 4637987 (561) 935-9955
noun email 3083073 info@marizyme.com 
Marizyme
© Copyright - 2023 Marizyme Inc. | All Rights Reserved | Website by Sandman Media Inc